MiR Scientific MiR Sentinel

MiR Scientific said it has launched its prostate cancer test MiR Sentinel in the United States, Puerto Rico and select international markets. The urine-based test analyzes small non-coding RNA using a proprietary biostatistical algorithm to assess the risk of aggressive prostate cancer and aid in the clinical management of men 45 years of age or older.

The current test is a refined and clinically validated version based on the firm's comprehensive miR Sentinel PCC4 assay, which received FDA Breakthrough Device Designation in the third quarter of 2020, as well as its original three-test model described in a proof-of-concept publication the same year.